What is required for Abilify Maintena administration?

Abilify Maintena is an injectable formulation of aripiprazole used for the treatment of schizophrenia and bipolar disorder. When initiating treatment with Abilify Maintena, it is essential to ensure adequate coverage as the medication begins to take effect.

The correct choice indicates that an overlap with oral medication is required for a duration of two weeks. This overlap is necessary because it allows the patient to maintain therapeutic levels of the medication in their system while transitioning from oral to injectable formulations. During this period, the oral form of the medication provides immediate efficacy, preventing any potential lapse in treatment during the transition to the injectable version, which may take some time to reach its full therapeutic effect.

This approach is important for patients who may not have previously been on medication or are switching treatments to ensure they remain stable and experience a smooth transition without exacerbation of their condition.